• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

研究诚信中的不当行为:评估Cochrane泌尿外科癌症综述小组系统评价的质量。

Misconduct in research integrity: Assessment the quality of systematic reviews in Cochrane urological cancer review group.

作者信息

Salehi-Pourmehr Hanieh, Naseri Amirreza, Mostafaei Ali, Vahedi Leila, Sajjadi Sana, Tayebi Sona, Mostafaei Hadi, Hajebrahimi Sakineh

机构信息

Research Center for Evidence Based-Medicine, Iranian EBM Center: A Joanna Briggs Institute Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran.

Research Center for Evidence Based-Medicine, Iranian EBM Center: A Joanna Briggs Institute Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

出版信息

Turk J Urol. 2021 Sep;47(5):392-419. doi: 10.5152/tud.2021.21038.

DOI:10.5152/tud.2021.21038
PMID:35118979
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9612768/
Abstract

OBJECTIVE

Cochrane Library provides a powerful and authoritative database to aid medical decision making. We aimed to evaluate the quality of clinical trials and systematic reviews recorded in the Cochrane urology cancers group.

MATERIAL AND METHODS

This analytic cross-sectional study was conducted on 44 published systematic reviews of the Cochrane urology group which were published until May 2020. In the current study, we selected the urological cancer reviews. All types of biases in the understudied randomized controlled trials (RCTs) or quasi-RCTs of these systematic reviews were evaluated using the Cochrane appraisal checklist. We also separated and stratified the types of biases in the included studies. In addition, the quality of systematic reviews was assessed using the Joanna Briggs Institute (JBI) appraisal checklist.

RESULTS

A total of 44 systematic reviews and their understudied 340 RCTs were evaluated. On the basis of the JBI appraisal checklist results, 93.2% of systematic reviews had high quality. In terms of the quality of understudied RCTs in these reviews, the common prevalent risk of bias of the understudied RCTs or quasi- RCTs was unclear selection bias (allocation concealment and random sequence generation). The highest risk of bias was seen in the blinding of participants and personnel (performance bias).

CONCLUSION

Although most Cochrane urological cancer reviews had high quality, performance bias was the highest one in their understudied RCTs. Regarding it and considering the increasing unclear risk of detection, attrition, and reporting biases, it is obvious that they have structural deficiencies; therefore, it is recommended to observe integrity principles for preventing research misconduct.

摘要

目的

Cochrane图书馆提供了一个强大且权威的数据库,以辅助医学决策。我们旨在评估Cochrane泌尿外科癌症小组记录的临床试验和系统评价的质量。

材料与方法

本分析性横断面研究针对截至2020年5月发表的Cochrane泌尿外科小组的44篇已发表系统评价进行。在本研究中,我们选择了泌尿外科癌症相关评价。使用Cochrane评估清单对这些系统评价中所研究的随机对照试验(RCT)或半随机对照试验中的各类偏倚进行评估。我们还对纳入研究中的偏倚类型进行了分类和分层。此外,使用乔安娜·布里格斯研究所(JBI)评估清单对系统评价的质量进行评估。

结果

共评估了44篇系统评价及其所研究的340项RCT。根据JBI评估清单结果,93.2%的系统评价质量较高。就这些评价中所研究的RCT质量而言,所研究的RCT或半随机对照试验中常见的主要偏倚风险是选择偏倚不明确(分配隐藏和随机序列生成)。偏倚风险最高的是参与者和人员的盲法(实施偏倚)。

结论

尽管大多数Cochrane泌尿外科癌症相关评价质量较高,但其所研究的RCT中实施偏倚最高。考虑到这一点以及检测、失访和报告偏倚的不明确风险增加,显然它们存在结构缺陷;因此,建议遵守诚信原则以防止研究不当行为。

相似文献

1
Misconduct in research integrity: Assessment the quality of systematic reviews in Cochrane urological cancer review group.研究诚信中的不当行为:评估Cochrane泌尿外科癌症综述小组系统评价的质量。
Turk J Urol. 2021 Sep;47(5):392-419. doi: 10.5152/tud.2021.21038.
2
Quality of the Systematic Reviews in Cochrane Gynecological Cancer Group and Their Understudied RCTs.考科蓝妇科癌症小组系统评价的质量及其未充分研究的随机对照试验
J Obstet Gynaecol India. 2022 Aug;72(Suppl 1):346-351. doi: 10.1007/s13224-022-01655-6. Epub 2022 Apr 13.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals.试验报告的统一标准(CONSORT)以及医学期刊上发表的随机对照试验(RCT)的报告完整性。
Cochrane Database Syst Rev. 2012 Nov 14;11(11):MR000030. doi: 10.1002/14651858.MR000030.pub2.
5
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
6
Risk of Bias in Iranian Randomized Trials Included in Cochrane Reviews.伊朗 Cochrane 综述纳入的随机试验偏倚风险。
Arch Iran Med. 2022 Jun 1;25(6):375-382. doi: 10.34172/aim.2022.61.
7
Agreement in Risk of Bias Assessment Between RobotReviewer and Human Reviewers: An Evaluation Study on Randomised Controlled Trials in Nursing-Related Cochrane Reviews.机器人评估者与人工评估者在偏倚风险评估中的一致性:一项针对 Cochrane 护理相关综述中随机对照试验的评估研究。
J Nurs Scholarsh. 2021 Mar;53(2):246-254. doi: 10.1111/jnu.12628. Epub 2021 Feb 8.
8
Quality assessment of reporting of randomization, allocation concealment, and blinding in traditional Chinese medicine RCTs: a review of 3159 RCTs identified from 260 systematic reviews.中文临床试验随机分配、隐藏和盲法报告质量评估:260 项系统评价中 3159 项随机对照试验的综述
Trials. 2011 May 13;12:122. doi: 10.1186/1745-6215-12-122.
9
10
Empirical evidence of study design biases in nutrition randomised controlled trials: a meta-epidemiological study.营养随机对照试验中研究设计偏倚的实证证据:一项meta 流行病学研究。
BMC Med. 2022 Oct 11;20(1):330. doi: 10.1186/s12916-022-02540-9.

引用本文的文献

1
Safety and Efficacy of Shaoyao Decoction with Anti-Inflammatory Effect in the Treatment of Ulcerative Colitis: A Meta-Analysis.具有抗炎作用的芍药汤治疗溃疡性结肠炎的安全性及有效性:一项Meta分析
Iran J Public Health. 2025 Mar;54(3):478-488. doi: 10.18502/ijph.v54i3.18241.

本文引用的文献

1
The Labyrinth of Renal Cell Carcinoma.肾细胞癌的迷宫
Cancers (Basel). 2020 Feb 24;12(2):521. doi: 10.3390/cancers12020521.
2
Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer.卡介苗膀胱灌注与丝裂霉素C治疗Ta和T1期膀胱癌的对比
Cochrane Database Syst Rev. 2020 Jan 8;1(1):CD011935. doi: 10.1002/14651858.CD011935.pub2.
3
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
4
Epigenetics of Urological Cancers.泌尿系统肿瘤的表观遗传学。
Int J Mol Sci. 2019 Sep 26;20(19):4775. doi: 10.3390/ijms20194775.
5
Hypofractionation for clinically localized prostate cancer.临床局限性前列腺癌的大分割放疗
Cochrane Database Syst Rev. 2019 Sep 3;9(9):CD011462. doi: 10.1002/14651858.CD011462.pub2.
6
Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer.晚期激素敏感性前列腺癌的早期与延迟标准雄激素抑制治疗
Cochrane Database Syst Rev. 2019 Jun 11;6(6):CD003506. doi: 10.1002/14651858.CD003506.pub2.
7
Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy.根治性膀胱切除术患者行扩大淋巴结清扫与标准淋巴结清扫治疗膀胱尿路上皮癌的比较
Cochrane Database Syst Rev. 2019 May 14;5(5):CD013336. doi: 10.1002/14651858.CD013336.
8
Perioperative nutrition for the treatment of bladder cancer by radical cystectomy.根治性膀胱切除术治疗膀胱癌的围手术期营养
Cochrane Database Syst Rev. 2019 May 20;5(5):CD010127. doi: 10.1002/14651858.CD010127.pub2.
9
Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma.上尿路尿路上皮癌肾输尿管切除术后的单剂量膀胱内化疗。
Cochrane Database Syst Rev. 2019 May 18;5(5):CD013160. doi: 10.1002/14651858.CD013160.pub2.
10
Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.用于检测前列腺癌的前列腺磁共振成像(MRI),无论是否进行MRI靶向活检及系统活检。
Cochrane Database Syst Rev. 2019 Apr 25;4(4):CD012663. doi: 10.1002/14651858.CD012663.pub2.